Venous thrombotic events in cancer: The bottom line

Cancer Control

Volumn 12, Issue SUPPL. 1, 2005, Pages 31-37

  Horton, John ^a  

^a H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANASTROZOLE; ANTINEOPLASTIC AGENT; ASPARAGINASE; BEVACIZUMAB; DALTEPARIN; ENOXAPARIN; EXEMESTANE; FONDAPARINUX; HEPARIN; LETROZOLE; LOW MOLECULAR WEIGHT HEPARIN; NADROPARIN; RECOMBINANT ERYTHROPOIETIN; TAMOXIFEN; THALIDOMID; THALIDOMIDE; TINZAPARIN; WARFARIN;

ANEMIA; BREAST CANCER; CANCER; CANCER PATIENT; CLINICAL TRIAL; DEEP VEIN THROMBOSIS; DIAGNOSTIC PROCEDURE; DRUG INDICATION; HIGH RISK PATIENT; HUMAN; HYPERCOAGULABILITY; LUNG EMBOLISM; PRACTICE GUIDELINE; PROGNOSIS; RECURRENCE RISK; REVIEW; RISK FACTOR; SYMPTOMATOLOGY; VENOUS THROMBOEMBOLISM;

EID: 25144483786     PISSN: 10732748     EISSN: None     Source Type: Journal    
DOI: 10.1177/1073274805012003s06     Document Type: Review

References (33)

1. The Seventh ACCP Consensus Conference on Antithrombotic and Thrombolytic Therapy: Evidence-Based Guidelines. Chest. 2004;126(3suppl).
2. Heit JA, O'Fallon WM, Petterson TM, et al. Relative impact of risk factors for deep vein thrombosis and pulmonary embolism: a population-based study. Arch Intern Med. 2002;162:1245-1248.
3. Blom JW, Doggen CJ, Osanto S, et al. Malignancies, prothrombotic mutations, and the risk of venous thrombosis. JAMA. 2005;293:715-722.
4. Lee AY, Julian JA, Levine MN, et al. Clinical utility of a rapid whole-blood D-dimer assay in patients with cancer who present with suspected acute deep venous thrombosis. Ann Intern Med. 1999;131:417-423.
5. Bick RL. Cancer-associated thrombosis. N Engl J Med. 2003;349:109-110.
6. Heit JA. Cancer and venous thromboembolism: scope of the problem. Cancer Control. 2005;12(suppl 1):5-10.
7. Miller GJ, Bauer KA, Howarth DJ, et al. Increased incidence of neoplasia of the digestive tract in men with persistent activation of the coagulant pathway. J Thromb Haemost. 2004;2:2107-2114.
8. Schulman S, Lindmarker P. Incidence of cancer after prophylaxis with warfarin against recurrent venous thromboembolism: duration of anticoagulation trial. N Engl J Med. 2000;342:1953-1958.
9. Sorensen HT, Mellemkjaer L, Olsen JH, et al. Prognosis of cancers associated with venous thromboembolism. N Engl J Med. 2000;343:1846-1850.
10. Heit JA, Silverstein MD, Mohr DN, et al. Risk factors for deep vein thrombosis and pulmonary embolism: a population-based case-control study. Arch Intern Med. 2000;160:809-815.
11. Sorensen HT, Mellemkjaer L, Nielsen GL, et al. Prognosis of cancers associated with venous thromboembolism. N Engl J Med. 2000;343:1846-1850.
12. Levitan N, Dowlati A, Remick SC, et al. Rates of initial and recurrent thromboembolic disease among patients with malignancy versus those without malignancy. Risk analysis using Medicare claims data. Medicine. 1999;78:285-291.
13. Levesque H, Belizna C, Michel P, et al. Venous thromboembolic treatment in patients with cancer (in French). Rev Med Interne. 2004;25:906-914.
14. Kakkar AK, Levine M, Pinedo HM, et al. Venous thrombosis in cancer patients: insights from the FRONTLINE survey. Oncologist. 2003;8:381-388.
15. Lee AY, Levine MN, Baker RI, et al. Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer. N Engl J Med. 2003;349:146-153.
16. Sallah S, Wan JY, Nguyen NP. Venous thrombosis in patients with solid tumors: determination of frequency and characteristics. Thromb Haemost. 2002;87:575-579:
17. Thodiyil PA, Kakkar AK. Variation in relative risk of venous thromboembolism in different cancers. Thromb Haemost. 2002;87:1076-1077.
18. Geerts WH, Pineo GF, Heit JA, et al. Prevention of venous thromboembolism. The Seventh ACCP Consensus Conference on Antithrombotic and Thrombolytic Therapy. Chest. 2004;126(3 suppl):338S-400S.
19. Bergqvist D, Burmark US, Flordal PA, et al. Low molecular weight heparin started before surgery as prophylaxis against deep vein thrombosis: 2500 versus 5000 Xal units in 2070 patients. Br J Surg. 1995;82:496-501.
20. Rasmussen MS. Does prolonged thromboprophylaxis improve outcome in patients undergoing surgery? Cancer Treat Rev. 2003;29(suppl 2):15-17.
21. ENOXACAN Study Group. Efficacy and safety of enoxaparin versus unfractionated heparin for prevention of deep vein thrombosis in elective cancer surgery: a double-blind randomized multicentre trial with venographic assessment. Br J Surg. 1997;84:1099-1103.
22. Alikhan R, Cohen AT, Combe S, et al. Prevention of venous thromboembolism in medical patients with enoxaparin: a subgroup analysis of the MEDENOX study. Blood Coagul Fibrinolysis. 2003;14:341-346.
23. Bauersachs RM. Fondaparinux: an update on new study results. Eur J Clin Invest. 2005;35(suppl 1):27-32.
24. Bonthier J. The venous thrombotic risk in non-surgical patients. Drugs. 1996;52(suppl):16-29.
25. Alikhan R, Peters F, Wilmott R, et al. Fatal pulmonary embolism in hospitalised patients: a necropsy review. J Clin Pathol. 2004;57:1254-1257.
26. Masci G, Magagnoli M, Zucali PA, et al. Minidose warfarin prophylaxis for catheter-associated thrombosis in cancer patients: can it be safely associated with fluorouracil-based chemotherapy? J Clin Oncol. 2003;21:736-739.
27. Reichart P, Kretzschmar A, Biakhov M, et al. A phase III double-blind, placebo-controlled study evaluating the efficacy and safety of daily low-molecular-weight heparin (dalteparin sodium, Fragmin) in preventing catheter-related complications in cancer patients with central venous catheters. Proc Annu Meet Am Soc Clin Oncol. 2002;21:1474. Abstract.
28. Hirsh J, Raschke R. Heparin and low-molecular-weight heparin. The Seventh ACCP Consensus Conference on Antithrombotic and Thrombolytic Therapy. Chest. 2004;126(3 suppl):188S-203S.
29. Baum M. Current status of aromatase inhibitors in the management of breast cancer and critique of the NCIC MA-17 trial. Cancer Control. 2004;11: 217-221.
30. Büller HR, Agnelli G, Hull RD, et al. Antithrombotic therapy for venous thromboembolic disease. The Seventh ACCP Consensus Conference on Antithrombotic and Thrombolytic Therapy. Chest. 2004;126(3 suppl):401S-428S.
31. Erratum in: Chest. 2005;127:416.
32. Hull RD, Pineo GF, Mah AF, et al. A randomized trial evaluating long-term low-molecular-weight heparin therapy for three months versus intravenous heparin followed by warfarin sodium. Blood. 2002;100:148a. Abstract.
33. Kakkar AK. Low-molecular-weight heparin and survival in patients with malignant disease. Cancer Control. 2005;12(suppl 1):22-30.